CTC Alternative Strategies Ltd. Acquires New Shares in Gilead Sciences, Inc. $GILD

Key Points

• CTC Alternative Strategies Ltd. acquired 7,000 shares of Gilead Sciences, Inc., valued at approximately $784,000, making Gilead 1.0% of its holdings.
• CEO Daniel Patrick O'Day sold 10,000 shares for about $1.14 million, and insider Johanna Mercier sold 28,000 shares for approximately $3.32 million.
• Gilead's latest earnings report showed an EPS of $2.01, beating estimates, while the company announced a quarterly dividend of $0.79 to be paid on September 29th.

CTC Alternative Strategies Ltd. purchased a new stake in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) in the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The fund purchased 7,000 shares of the biopharmaceutical company's stock, valued at approximately $784,000. Gilead Sciences makes up 1.0% of CTC Alternative Strategies Ltd.'s holdings, making the stock its 24th biggest holding.

Several other large investors have also made changes to their positions in GILD. Redwood Financial Network Corp boosted its position in shares of Gilead Sciences by 4.0% in the fourth quarter. Redwood Financial Network Corp now owns 2,530 shares of the biopharmaceutical company's stock valued at $234,000 after acquiring an additional 98 shares during the period. Argentarii LLC lifted its holdings in shares of Gilead Sciences by 3.0% during the first quarter. Argentarii LLC now owns 3,392 shares of the biopharmaceutical company's stock valued at $380,000 after acquiring an additional 99 shares during the period. Peak Financial Advisors LLC lifted its holdings in shares of Gilead Sciences by 1.7% during the first quarter. Peak Financial Advisors LLC now owns 6,040 shares of the biopharmaceutical company's stock valued at $677,000 after acquiring an additional 100 shares during the period. Perkins Coie Trust Co lifted its holdings in shares of Gilead Sciences by 2.6% during the first quarter. Perkins Coie Trust Co now owns 3,880 shares of the biopharmaceutical company's stock valued at $435,000 after acquiring an additional 100 shares during the period. Finally, Investment Research & Advisory Group Inc. lifted its holdings in shares of Gilead Sciences by 33.3% during the first quarter. Investment Research & Advisory Group Inc. now owns 400 shares of the biopharmaceutical company's stock valued at $45,000 after acquiring an additional 100 shares during the period. Institutional investors own 83.67% of the company's stock.

Insider Buying and Selling

In other Gilead Sciences news, CEO Daniel Patrick O'day sold 10,000 shares of the firm's stock in a transaction on Thursday, August 28th. The stock was sold at an average price of $113.63, for a total transaction of $1,136,300.00. Following the completion of the sale, the chief executive officer owned 595,725 shares of the company's stock, valued at $67,692,231.75. This trade represents a 1.65% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Johanna Mercier sold 28,000 shares of the firm's stock in a transaction on Friday, August 15th. The shares were sold at an average price of $118.53, for a total value of $3,318,840.00. Following the sale, the insider directly owned 114,168 shares of the company's stock, valued at $13,532,333.04. This represents a 19.70% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 82,000 shares of company stock worth $9,371,330. 0.27% of the stock is owned by corporate insiders.

Analyst Ratings Changes

GILD has been the subject of a number of research analyst reports. Daiwa Capital Markets raised Gilead Sciences from a "neutral" rating to an "outperform" rating and set a $128.00 price target for the company in a report on Tuesday, August 19th. Daiwa America upgraded Gilead Sciences from a "hold" rating to a "strong-buy" rating in a research report on Tuesday, August 19th. Royal Bank Of Canada boosted their price objective on Gilead Sciences from $96.00 to $98.00 and gave the company a "sector perform" rating in a research report on Friday, August 8th. UBS Group boosted their price objective on Gilead Sciences from $108.00 to $112.00 and gave the company a "neutral" rating in a research report on Friday, August 8th. Finally, Needham & Company LLC upgraded Gilead Sciences from a "hold" rating to a "buy" rating and set a $133.00 price objective for the company in a research report on Friday, July 25th. Three analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and six have given a Hold rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $115.39.

Gilead Sciences Trading Up 2.0%

NASDAQ:GILD opened at $115.05 on Monday. The company has a market cap of $142.76 billion, a P/E ratio of 22.92, a price-to-earnings-growth ratio of 0.78 and a beta of 0.36. The company has a quick ratio of 1.15, a current ratio of 1.32 and a debt-to-equity ratio of 1.13. Gilead Sciences, Inc. has a twelve month low of $78.26 and a twelve month high of $121.83. The business has a 50 day moving average price of $113.59 and a two-hundred day moving average price of $109.90.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last released its quarterly earnings data on Thursday, August 7th. The biopharmaceutical company reported $2.01 EPS for the quarter, beating the consensus estimate of $1.96 by $0.05. The company had revenue of $7.08 billion during the quarter, compared to the consensus estimate of $6.95 billion. Gilead Sciences had a return on equity of 50.99% and a net margin of 21.86%.The firm's revenue for the quarter was up 1.4% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $2.01 EPS. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. As a group, analysts expect that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Monday, September 29th. Stockholders of record on Monday, September 15th will be issued a $0.79 dividend. This represents a $3.16 annualized dividend and a dividend yield of 2.7%. The ex-dividend date of this dividend is Monday, September 15th. Gilead Sciences's dividend payout ratio is presently 62.95%.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.